BCAL Diagnostics secures extra A$4.9m to fund cancer detection portfolio

• BCAL Diagnostics (ASX:BDX) has locked in an extra A$4.9 million under its existing A$10 million convertible note facility
• The company expects about A$2.5 million in FY26 R&D tax offset funding, with A$1.4 million due around 30 June and the balance in October
• BCAL Diagnostics (ASX:BDX) says the funds will support development and commercialisation of its blood‑based early cancer detection portfolio through FY2027

BCAL Diagnostics (ASX:BDX), an Australian healthcare company focused on early cancer detection, has secured firm commitments for a further A$4.9 million under its existing A$10 million convertible note facility, with the additional funds to be drawn down as required.

BCAL also expects to receive the first tranche of its FY26 R&D tax offset of A$1.4 million around 30 June 2026, representing about 56 per cent of an anticipated A$2.5 million total offset, with the remaining A$1.1 million due in October 2026.

“We are delighted with the additional financing commitment for the balance of the Convertible Note facility,” said BCAL Diagnostics Chief Executive Officer Anne‑Louise Arnett.

BCAL states that the combined funding will support ongoing investment to develop and commercialise its blood‑based early cancer detection portfolio and underpin planned activities through FY2027, with the R&D tax offset described as an important source of non‑dilutive capital.

The company’s available early detection portfolio includes its BREASTESTplus blood test for women with dense breasts, BREASTESTplus Version 2 and BREASTEST Monitor, as well as licensed Avantect pancreatic, Avantect ovarian and Avantect multi‑cancer blood tests for Australia and New Zealand.

BCAL says its commercialisation strategy is focused on making simple blood‑based cancer tests more accessible to doctors and patients, positioning BREASTESTplus as a “rule‑out” test used alongside mammography and leveraging its exclusive distribution agreement with US‑based ClearNote Health for Avantect products in local markets.

At the time of reporting BCAL Diagnostics (ASX:BDX) share price was $0.00.